Dr Camille Carroll
Profiles

Dr Camille Carroll

Post Doctoral Research Fellow in Clinical Neuroscience

Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of M

Role

Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust

Parkinson's Disease Specialty Lead and Division 2 Clinical Research Lead South West Peninsula CRN

Chair of Peninsula Parkinson's Excellence Network

Qualifications

I undertook preclinical medical training at the University of Manchester, where I also completed an intercalated PhD (1994)  under the supervision of Jon Brotchie and Ian Mitchell, investigating NMDA receptor antagonists in animal models of Parkinson's disease. I completed my clinical training at the University of Oxford in 1997, before undertaking junior medical positions in Oxford, Bath and London (including NHNN), gaining MRCP in 2000. I undertook my neurology specialist training in the South West and West Midlands Deaneries with posts in Plymouth, Bristol, Birmingham and Coventry. I entered the specialist register in Jan 2007.

Realising the importance and potential of molecular biology as a field that had developed enormously since my PhD, I was awarded an MRC clinical research training fellowship for post-doctoral students who need retraining in 2007. This has allowed me to develop research interests investigating neuroprotective mechanisms in cell culture models of Parkinson's disease. My current focus is on early disease detection and clinical trials of neuroprotective interventions in Parkinson's disease.

Roles on external bodies

I am Specialty Lead for Parkinson's disease in SWP CRN and also Division 2 Clinical Specialty Lead. I sit on the national Clinical Studies Group in Parkinson's disease. I am a member of the Question Writing Group (since 2005), Standard Setting Group (since 2007) and examining board (since 2015) for the Neurology SCE (RCP).

Research interests

I have experience of behavioural pharmacology in animal models of Parkinson’s disease, and more recently have developed an interest in mechanisms of cell death and neuroprotective strategies. I have established a PD cell culture model which we utilize to investigate the neuroprotective effects of cannabinoids and endocannabinoid modulators, focusing on the intracellular downstream mechanisms mediating their effects. I have active collaborations locally and nationally investigating other aspects of PD pathogenesis including pre-symptomatic bowel alpha-synuclein expression, lysosomal pathways in Drosphila and verifying our cell culture findings in an in vivo mouse model. I currently co-supervise 2 PhD students and several placement students. I have previously contributed to studies of surgical intervention in Parkinson’s disease (PD), both in the UK and in the US, and planned and managed a clinical trial of cannabinoids for symptomatic therapy in PD. I am currently part of the NIHR-funded team investigating clinical trial methodology in neurodegenerative diseases, investigating outcome measures of various parameters in PD. I am joint PD research director for SW DeNDRoN and as such have responsibility for overseeing clinical research capability in the Peninsula and the development of a balanced clinical trial portfolio. I am PI on a number of clinical studies and have overseen the development of a PD DNA bank (1500 samples) and PD clinical research register.

Research groups

Key publications are highlighted

Journals
Articles
Zeissler M-L, Eastwood J, McCorry K, Hanemann OC, Zajicek JP & Carroll CB 2016 'Delta-9-tetrahydrocannabinol protects against MPP<sup>+</sup> toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis' Oncotarget , DOI PEARL
Jammeh E, Zhao P, Carroll C, Pearson S & Ifeachor E 2016 'Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease' 2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) 2415-2418 Author Site PEARL
Lubbe SJ, Escott-Price V, Brice A, Gasser T, Pittman AM, Bras J, Hardy J, Heutink P, Wood NM & Singleton AB 2016 'Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease' Neurobiology of Aging 48, 222.e1-222.e7 , DOI
Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C & Kessel B 2015 'King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation' Movement Disorders 30, (12) 1623-1631 , DOI PEARL
Kamel Boulos MN, Ifeachor E, Escudero Rodriguez J, Zhao P, Carroll CB, Costa P, Doppler G, Carrasco L, Spiru L & Helga K 2015 'LiveWell - Promoting Healthy Living and Wellbeing for Parkinson Patients Through Social Network and ICT Training: Lessons Learnt and Best Practices' International Journal of Healthcare Information Systems and Informatics
Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H & Carroll C 2013 'Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease' Acta Neuropathologica 1-7 Author Site , DOI
Cooke T, Carroll C, Zajicek J, Ellard S & Morrison K 2013 'Molecular genetic studies of neurodegenerative disease' J Neurol Neurosurg Psychiatry 84, (11) Author Site , DOI PEARL
Zeissler ML, Eastwood J, Oliver Hanemann C, Zajicek J & Carroll C 2013 'Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' Journal of Neurology, Neurosurgery & Psychiatry 84, (11) e2.58-e2 , DOI PEARL
Carroll C, Palmer A, Cosby C & Zajicek J 2012 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' Clin Med (Lond) 12, (3) 210-215 Author Site PEARL
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO 2012 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 Author Site , DOI PEARL
Carroll CB, Zeissler M-L, Hanemann CO & Zajicek JP 2012 'Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease' Neuropathol Appl Neurobiol 38, (6) 535-547 Author Site , DOI
Carroll CB, Palmer A, Cosby C & Zajicek JP 2011 'Analysis and validation of a Parkinson's disease register as a recruitment tool for clinical studies' Trials 12 Suppl 1, , DOI
Carroll CB, Zeissler M-L, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE & Hanemann CO 2011 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, (1) 73-80 Author Site , DOI PEARL
Carroll CB & Zajicek JP 2011 'Designing clinical trials in older people' Maturitas 68, (4) 337-341 Author Site , DOI PEARL
Carroll CB, Zeissler ML, Stone V, Hanemann CO & Zajicek JP 2010 'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease' MOVEMENT DISORDERS 25, S621-S621 Author Site PEARL
Zeissler, Carroll CB & Zajicek J 2010 'CBD & D9-THC - the two faces of cannabis' Cell Science 7, (1)
Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams GJ, Morrison KE, Zajicek JP & Hanemann CO 2010 'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD' MOVEMENT DISORDERS 25, S628-S628 Author Site PEARL
Sinclair AJ, Carroll C & Davies B 2009 'Cauda equina syndrome following a lumbar puncture' J Clin Neurosci 16, (5) 714-716 Author Site , DOI PEARL
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J 2007 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 Author Site , DOI
Carroll CB, Tengah DSNAP, Lawthom C & Venables G 2007 'The feminisation of British neurology: implications for workforce planning' Clin Med (Lond) 7, (4) 339-342 Author Site PEARL
Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O & Morrison KE 2005 'Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS' Neurology 65, (6) 934-937 Author Site , DOI
Liu XG, Carroll CB, Wang SY, Zajicek J & Bain PG 2005 'Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks' JOURNAL OF NEUROSCIENCE METHODS 144, (1) 47-52 Author Site , DOI PEARL
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J 2004 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 Author Site
Carroll CB & Gardner-Thorpe C 2004 'Charles Karsner Mills (1845-1931) and his syndrome' Some Aspects of History of Neuroscience 35-36
Carroll CB & Bain PG 2004 'Doon-off variations cause discrepancies in the historical items of the UPDRS?' Movement Disorders 19, (5) 605-605 , DOI PEARL
Carroll C & Zajicek J 2004 'Provision of 24 hour acute neurology care by neurologists: manpower requirements in the UK' J Neurol Neurosurg Psychiatry 75, (3) 406-409 Author Site PEARL
Hadjikoutis S, Carroll CB & Plant GTP 2004 'Raised intracranial pressure presenting with spontaneous periorbital bruising: two case reports' Journal of Neurology, Neurosurgery and Psychiatry 75, (8) PEARL
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2004 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 Author Site PEARL
Fox P, Bain PG, Glickman S, Carroll C & Zajicek J 2004 'The effect of cannabis on tremor in patients with multiple sclerosis' Neurology 62, (7) 1105-1109 Author Site
Carroll CB & Zajicek JP 2004 'The 'harlequin' sign in association with multiple sclerosis' JOURNAL OF NEUROLOGY 251, (9) 1145-1146 Author Site , DOI
Weeks RA, Scaravilli F, Lees AJ, Carroll CB, Husain M & Rudge P 2003 'Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome' Movement Disorders 18, (3)
Cooper AJ, Carroll CB & Mitchell IJ 1998 'Glutamate antagonists for Parkinson's disease - Rationale for use and therapeutic implications' CNS DRUGS 9, (6) 421-429 Author Site , DOI
Scott R 1998 'Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures' Brain 121, (4) 659-675 , DOI
Carroll CB, Scott R, Davies LE & Aziz T 1998 'The pallidotomy debate' British Journal of Neurosurgery 2, (12)
Biousse V, Newman NJ, Carroll CB, Mewes K, Vitek JL, Bakay RAE, Baron MS & DeLong MR 1998 'Visual fields in patients with posterior GPi pallidotomy'
Mitchell IJ & Carroll CB 1997 'Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action' Neurosci Biobehav Rev 21, (4) 469-475 Author Site PEARL
Carroll CB, Holloway V, Brotchie JM & Mitchell IJ 1995 'Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms' Psychopharmacology 119, (1) 55-65 , DOI
MITCHELL IJ, HUGHES N, CARROLL CB & BROTCHIE JM 1995 'REVERSAL OF PARKINSONIAN SYMPTOMS BY INTRASTRIATAL AND SYSTEMIC MANIPULATIONS OF EXCITATORY AMINO-ACID AND DOPAMINE TRANSMISSION IN THE BILATERAL 6-OHDA LESIONED MARMOSET' BEHAVIOURAL PHARMACOLOGY 6, (5-6) 492-507 Author Site
Brotchie JM, Crossman ARC, Mitchell IJ, Duty S, Carroll CB, Cooper AJC, Henry B, Hughes N & Maneuf Y 1993 'Chemical signalling in the globus pallidus in parkinsonism' Progress in Brain Research (99) 125-139
Letters
Carroll C, Krolikowski K, Mukonoweshuro W, Jones J & Hanemann CO 2010 'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon' J Neurol 257, (12) 2094-2096 Author Site , DOI
Carroll CB, Hilton DA, Hamon M & Zajicek JP 2005 'Muscle cramps and weakness secondary to graft versus host disease fasciitis' Eur J Neurol 12, (4) 320-322 Author Site , DOI PEARL
Conference Papers
Pujara P, Rideout J & Carroll C 2016 'IMPROVING PROVISION OF PARKINSON'S DISEASE EXERCISE CLASSES' //0 //0 , DOI
Blight B, Davis J, Evans V, Hawkes N & Carroll C 2016 'IMPROVING THE EXPERIENCE OF DIAGNOSIS IN PARKINSON'S DISEASE' //0 //0 , DOI
Carroll C, Wagner A, Watson P, Spoudeas H, Hawkins M, Walker D, Clare I, Holland T & Ring H 2016 'LONG-TERM COGNITIVE OUTCOME IN ADULT SURVIVORS OF AN EARLY CHILDHOOD POSTERIOR FOSSA BRAIN TUMOUR' //0 //0 154-154
Dominey T, Newman C, Carroll C, Noad R, Appleyard B, Deeprose C & Hall S 2016 'PD-TAP: AN OBJECTIVE AND AUTOMATED MEASURE OF PARKINSON'S DISEASE SEVERITY' //0 //0 , DOI
Hilton DA, Stephens M, Zajicek J, Broughton E, Hagan H, Edwards P & Carroll C 2013 'Accumulation of alpha synuclein in the bowel in preclinical Parkinson's disease' //0 //0 11-11
Hilton DA, Zeissler ML, Zhang H, Zajicek J, Hicks J, Eastwood J & Carroll C 2013 'Cannabinoid receptor expression in Parkinson's disease' //0 //0 34-35
Zeissler M, Hanemann CO, Zajicek JP & Carroll CB 2012 'FAAH INHIBITION IS PROTECTIVE IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' //0 //0 , DOI
Carroll C, Zajicek JP, Hanemann CO, Stone V & Zeissler M 2010 'CANNABINOIDS ARE NEUROPROTECTIVE IN A HUMAN CELL CULTURE MODEL OF PARKINSON'S DISEASE' //0 //0 E60-E60 , DOI
Carroll C, Williams GJ, Chadborn NH, Hanemann CO, Zajicek JP, Morrison KE, Gibson K & Zeissler M 2010 'CHANGES IN IRON-REGULATORY GENE EXPRESSION OCCUR IN HUMAN CELL CULTURE MODELS OF PARKINSON'S DISEASE' //0 //0 E29-E29 , DOI
Carroll CB, Chadborn N, Hanemann O & Zajicek J 2009 'CANNABINOIDS ARE NEUROPROTECTIVE IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' //0 //0 , DOI
Sinclair AJ, Carroll C & Davies MB 2007 'A rare complication of a common procedure: Acute cauda equina syndrome following a lumbar puncture' //0 //0 218-218
Carroll CB, Majumdar D, Winer JB & Davies NP 2005 'Childhood onset demyelinating neuropathy and cataracts: A potentially treatable disorder' //0 //0 1323-1324
Carroll CB & Zajicek JP 2005 'Clinical viral encephalitis in adults: A 10 year retrospective study' //0 //0 157-158
Carroll C & Gardner-Thorpe C 2003 'Charles Karsner Mills (1845-1931) and his syndrome' //0 //0 406-406
Carroll CB & Zajicek JZ 2003 'Meeting the Association of British Neurologists guidelines: Provision of 24 hour acute neurology care by neurologists' //0 //0 1453-1453
Carroll C, Hobart J, Fox C, Teare L & Gibson J 2003 'Stroke in Devon: The need to translate knowledge into action' //0 //0 1176-1177